Know Cancer

or
forgot password

Chemotherapy Resistance in Osteogenic Sarcoma and Other Solid Tumors


N/A
N/A
N/A
Open (Enrolling)
Both
Osteosarcoma

Thank you

Trial Information

Chemotherapy Resistance in Osteogenic Sarcoma and Other Solid Tumors


When tumor tissue known or presumed to be a primary or secondary bone cancer or solid tumor
with known elevated intra-tumoral pressure such as retinoblastoma is being removed or has
been removed for diagnostic or therapeutic reasons a small sample of it will be obtained for
this study. The tumor samples will be used to study in vitro, determinants of chemotherapy
resistance and oncogenesis. These determinants will be correlated with histologic response
to preoperative chemotherapy and clinical outcome (event free survival). In addition, blood
samples (20ml) may be obtained before or after the procedure.


Inclusion Criteria:



- All patients with a presumed or known diagnosis of a primary or secondary bone cancer
or other solid tumor who are having or have had a biopsy or surgery to remove tumor
for diagnostic or therapeutic reasons. No tumors will be obtained solely for research
purposes.

- All adult patients (> or = to 18 yrs.) will have given written informed consent.

- All minor patients (<18 yrs.) will have given assent to the best of their ability to
understand, and their parent or guardian will have given written informed consent

Exclusion Criteria:

- N/A

Type of Study:

Interventional

Study Design:

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Outcome Measure:

To test tumor samples obtained from patients with primary or secondary bone cancer for mechanisms of acquired and intrinsic resistance to methotrexate and to relate these findings to histologic response to preoperative chemotherapy and outcome.

Outcome Time Frame:

2 years

Safety Issue:

No

Principal Investigator

John Healey, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Memorial Sloan-Kettering Cancer Center

Authority:

United States: Institutional Review Board

Study ID:

97-094

NCT ID:

NCT00580385

Start Date:

August 1997

Completion Date:

August 2014

Related Keywords:

  • Osteosarcoma
  • BONE
  • Osteosarcoma
  • Sarcoma

Name

Location

Memorial Sloan-Kettering Cancer CenterNew York, New York  10021